Wingate Wealth Advisors’s AbbVie ABBV Stock Holding History

Wingate Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$17.8K	–	93
2024 Q4	$17.8K	Buy	+100	New	+$18.4K	0.02%	299

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wingate Wealth Advisors's ABBV Position: Q1 2025 in Review

Wingate Wealth Advisors sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 100 shares — an estimated $17.8K sold.

Wingate Wealth Advisors first reported a position in ABBV in Q4 2024 and held it in 1 quarter. The position peaked at $17.8K in Q4 2024. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

Wingate Wealth Advisors reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
Wingate Wealth Advisors sold 100 AbbVie shares in Q1 2025, an estimated $17.8K.
Wingate Wealth Advisors first reported a position in AbbVie in Q4 2024 and held it in 1 quarter.
Wingate Wealth Advisors's AbbVie position peaked at $17.8K in Q4 2024.
3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Wingate Wealth Advisors's 13F filing for Q1 2025, filed 24 Apr 2025.